Company
Apil
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
13
4 still marketed
Novel approvals
2
Approvals since 2021
0
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Asacol new use May 27, 2015
- Asacol new use Oct 18, 2013
- Lo Minastrin Fe approved Jul 24, 2013
- Minastrin 24 Fe approved May 8, 2013
- Taytulla approved Apr 19, 2013
- Lo Loestrin Fe approved Oct 21, 2010
- Atelvia approved Oct 8, 2010
- Actonel new use Priority reviewJul 23, 2009
- Actonel new use Apr 22, 2008
- Actonel new use Apr 16, 2007
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (4)
Newest FDA action first.
- Atelvia Risedronate Sodium · 2010
- Actonel Risedronate Sodium · 1998
- Taytulla Ethinyl Estradiol, Norethindrone Acetate · 2013
- Lo Loestrin Fe Ethinyl Estradiol, Norethindrone Acetate · 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.